Reduced expression or epigenetic silencing of the mitotic checkpoint gene “checkpoint with fork-head and ringfinger domains” (CHFR) has recently been identified as powerful predictor for taxane sensitivity in gastric-, colon and lung cancer [ 1 x [1] Brandes, J.C., van Engeland, M., Wouters, K.A., Weijenberg, M.P., and Herman, J.G. CHFR promoter hypermethylation in colon cancer correlates with the microsatellite instability phenotype. Carcinogenesis. 2005; 26: 1152–1156 Crossref | PubMed | Scopus (69) | Google Scholar See all References , 2 x [2] Derks S, Cleven AH, Melotte V, Smits KM, Brandes JC, Azad N, van Criekinge W, de Bruine AP, Herman JG, van Engeland M. Emerging evidence for CHFR as a cancer biomarker: from tumor biology to precision medicine. Cancer Metastasis Rev. Google Scholar See all References , 3 x [3] Pillai, R.N., Brodie, S.A., Sica, G.L., Shaojin, Y., Li, G., Nickleach, D.C., Yuan, L., Varma, V.A., Bonta, D., Herman, J.G., Brock, M.V., Ribeiro, M.J., Ramalingam, S.S., Owonikoko, T.K., Khuri, F.R., and Brandes, J.C. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res – Off J Am Assoc Cancer Res. 2013; 19: 1603–1611 Crossref | PubMed | Scopus (15) | Google Scholar See all References ]. Reduced CHFR expression in patients with non-small lung cancer (NSCLC) who received first-line chemotherapy with carboplatin and paclitaxel predicts clinical benefit (81% vs. 48%, p = 0.03) and overall survival (HR = 0.24; 95% CI, 0.1–0.58%; P = 0.002) [ 3 x [3] Pillai, R.N., Brodie, S.A., Sica, G.L., Shaojin, Y., Li, G., Nickleach, D.C., Yuan, L., Varma, V.A., Bonta, D., Herman, J.G., Brock, M.V., Ribeiro, M.J., Ramalingam, S.S., Owonikoko, T.K., Khuri, F.R., and Brandes, J.C. CHFR protein expression predicts outcomes to taxane-based first line therapy in metastatic NSCLC. Clin Cancer Res – Off J Am Assoc Cancer Res. 2013; 19: 1603–1611 Crossref | PubMed | Scopus (15) | Google Scholar See all References ] [3] . These are important observations since it allows physicians to select patients for microtubular-targeted therapy based on their CHFR expression status, and furthermore, to target CHFR pharmacologically to overcome taxane resistance in patients whose tumors display high CHFR expression. NSCLC can be molecularly characterized by the presence of mutations in oncogenes and tumor suppressor genes, which frequently determine the therapeutic approach to these tumors. Targeted therapies for tumors with EGFR mutations [ 4 x [4] Lynch, T.J., Bell, D.W., Sordella, R., Gurubhagavatula, S., Okimoto, R.A., Brannigan, B.W., Harris, P.L., Haserlat, S.M., Supko, J.G., Haluska, F.G., Louis, D.N., Christiani, D.C., Settleman, J., and Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350: 2129–2139 Crossref | PubMed | Scopus (8594) | Google Scholar See all References , 5 x [5] Sordella, R., Bell, D.W., Haber, D.A., and Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004; 305: 1163–1167 Crossref | PubMed | Scopus (1313) | Google Scholar See all References , 6 x [6] Paez, J.G., Janne, P.A., Lee, J.C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F.J., Lindeman, N., Boggon, T.J., Naoki, K., Sasaki, H., Fujii, Y., Eck, M.J., Sellers, W.R., Johnson, B.E., and Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004; 304: 1497–1500 Crossref | PubMed | Scopus (7295) | Google Scholar See all References ] and Alk-translocations [ 7 x [7] Kwak, E.L., Bang, Y.J., Camidge, D.R., Shaw, A.T., Solomon, B., Maki, R.G., Ou, S.H., Dezube, B.J., Janne, P.A., Costa, D.B., Varella-Garcia, M., Kim, W.H., Lynch, T.J., Fidias, P., Stubbs, H., Engelman, J.A., Sequist, L.V., Tan, W., Gandhi, L., Mino-Kenudson, M., Wei, G.C., Shreeve, S.M., Ratain, M.J., Settleman, J., Christensen, J.G., Haber, D.A., Wilner, K., Salgia, R., Shapiro, G.I., Clark, J.W., and Iafrate, A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363: 1693–1703 Crossref | PubMed | Scopus (3136) | Google Scholar See all References ] [7] are available and new targets such as RET and ROS1 fusions, BRAF, and ERBB2, are rapidly emerging. Nonetheless, a large percentage of lung cancers are not driven by single oncogene mutations and improvements in better selection of standard chemotherapy drugs or the development of novel targeted approaches to overcome chemo-resistance are essential for patients with these tumors. To find the most appropriate place for CHFR testing in the ever more complex algorithms for biomarker analysis in NSCLC, it is important to determine if reduced expression of CHFR is tied exclusively to certain molecularly defined subtypes of NSCLC or, conversely, if CHFR expression is independent from the presence of lung cancer specific mutations. We therefore analyzed CHFR expression and frequent relevant mutations in NSCLC reported in The Cancer Genome Atlas (TCGA) for both adenocarcinoma (EGFR, KRAS, ALK, MET, ERBB2, TP53, STK11, ROS1, RET, NF1, Pik3CA) and squamous cell carcinoma (FGFR1, FGFR2, FGFR3, TP53, STK11, EGFR).